CVE-2004-2730

Description

Sysinternals PsTools before 2.05, including (1) PsExec before 1.54, (2) PsGetsid before 1.41, (3) PsInfo before 1.61, (4) PsKill before 1.03, (5) PsList before 1.26, (6) PsLoglist before 2.51, (7) PsPasswd before 1.21, (8) PsService before 2.12, (9) PsSuspend before 1.05, and (10) PsShutdown before 2.32, does not properly disconnect from remote IPC$ and ADMIN$ shares, which allows local users to access the shares with elevated privileges by using the existing share mapping.

Category

4.6
CVSS
Severity: Medium
CVSS 2.0 •
EPSS 0.92% Top 30%
Vendor Advisory secunia.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://www3.ca.com/securityadvisor/vulninfo/vuln.aspx?id=28304
http://www.securityfocus.com/bid/10759 vdb entry patch
http://secunia.com/advisories/12108 third party advisory vendor advisory
http://securitytracker.com/id?1010737 vdb entry
http://www.osvdb.org/8140 vdb entry
https://exchange.xforce.ibmcloud.com/vulnerabilities/16743 vdb entry

Frequently Asked Questions

What is the severity of CVE-2004-2730?
CVE-2004-2730 has been scored as a medium severity vulnerability.
How to fix CVE-2004-2730?
To fix CVE-2004-2730, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2004-2730 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2004-2730 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.